ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours

[1]  E. Whitlock,et al.  Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force , 2016, Annals of Internal Medicine.

[2]  P. Elwood,et al.  Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies , 2016, PloS one.

[3]  C. V. D. van de Velde,et al.  The effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patients , 2016, British Journal of Cancer.

[4]  T. Kim,et al.  The effect of prediagnostic aspirin use on the prognosis of stage III colorectal cancer. , 2015, International journal of clinical and experimental medicine.

[5]  B. Møller,et al.  Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal cancer: A population-based study. , 2015 .

[6]  S. Zhong,et al.  Association between aspirin use and mortality in breast cancer patients: a meta-analysis of observational studies , 2015, Breast Cancer Research and Treatment.

[7]  S. Ozawa,et al.  Impact of preoperative neutrophil to lymphocyte ratio on long-term survival in patients with esophageal squamous cell carcinoma. , 2015 .

[8]  N. Cook,et al.  Estimates of benefits and harms of prophylactic use of aspirin in the general population , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  J. Meyerhardt,et al.  Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. , 2015, Journal of the National Cancer Institute.

[10]  S. Freedland,et al.  Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Royston,et al.  An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect , 2014, Trials.

[12]  C. McCowan,et al.  Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study , 2014, British Journal of Cancer.

[13]  D. Kerr,et al.  Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  N. Cook,et al.  Alternate-Day, Low-Dose Aspirin and Cancer Risk: Long-Term Observational Follow-up of a Randomized Trial , 2013, Annals of Internal Medicine.

[15]  R. Jorissen,et al.  Aspirin use and survival outcomes in patients (pts) with PIK3CA mutant colorectal cancer (CRC). , 2013 .

[16]  T. Yeatman,et al.  Association of aspirin use with improved 5-year survival in colorectal cancer patients with PIK3CA mutation. , 2013 .

[17]  P. Donnan,et al.  Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. , 2013, European journal of cancer.

[18]  D. Bishop,et al.  Edinburgh Research Explorer Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer , 2022 .

[19]  Reiko Nishihara,et al.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.

[20]  Sujoy Ghosh,et al.  Prostate Cancer, Androgen Deprivation Therapy, Obesity, the Metabolic Syndrome, Type 2 Diabetes, and Cardiovascular Disease: A Review , 2012, American journal of clinical oncology.

[21]  A. Walker,et al.  Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study , 2012, British Journal of Cancer.

[22]  E. Horwitz,et al.  Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy. , 2012, International journal of radiation oncology, biology, physics.

[23]  Anthony V D'Amico,et al.  Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Cuzick,et al.  Aspirin and cancer risk: a quantitative review to 2011. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  M. Parmar,et al.  Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial , 2012, The Lancet. Oncology.

[26]  P. Rothwell,et al.  Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. , 2012, The Lancet. Oncology.

[27]  M. Thun,et al.  The role of aspirin in cancer prevention , 2012, Nature Reviews Clinical Oncology.

[28]  P. Rothwell,et al.  Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials , 2012, The Lancet.

[29]  Gianni Tognoni,et al.  Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials , 2012, The Lancet.

[30]  O. Dekkers,et al.  Use of Aspirin postdiagnosis improves survival for colon cancer patients , 2012, British Journal of Cancer.

[31]  S. Gallus,et al.  Aspirin and urologic cancer risk: an update , 2012, Nature Reviews Urology.

[32]  Rodney J Scott,et al.  Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial , 2011, The Lancet.

[33]  R. Ali,et al.  The utility of Aspirin in dukes C and high risk dukes B colorectal cancer - The ASCOLT study: study protocol for a randomized controlled trial , 2011, Trials.

[34]  A. Fulton,et al.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer , 2011, Cancer and Metastasis Reviews.

[35]  Richard O Hynes,et al.  Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. , 2011, Cancer cell.

[36]  Karol Sikora,et al.  Delivering affordable cancer care in high-income countries. , 2011, The Lancet. Oncology.

[37]  S. Burdett,et al.  Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? , 2011, British Journal of Cancer.

[38]  R. Dikshit,et al.  Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  G. Colditz,et al.  COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin , 2011, Breast Cancer Research and Treatment.

[40]  P. Rothwell,et al.  Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials , 2011, The Lancet.

[41]  A. Ruíz,et al.  Adjuvant docetaxel for high-risk, node-negative breast cancer. , 2010, The New England journal of medicine.

[42]  C. Mathers,et al.  Chronic Diseases: Chronic Diseases and Development 5 Monitoring and surveillance of chronic non-communicable diseases: progress and capacity in high-burden countries , 2010 .

[43]  A. Algra,et al.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.

[44]  Mats Lambe,et al.  Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Donna Spiegelman,et al.  Aspirin intake and survival after breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  A. Algra,et al.  Long-term eff ect of aspirin on colorectal cancer incidence and mortality : 20-year follow-up of fi ve randomised trials , 2010 .

[47]  S. Ogino,et al.  Aspirin Use and Survival After Diagnosis of Colorectal Cancer , 2009 .

[48]  W. Allum,et al.  Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[51]  I. Ellis,et al.  Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial , 2009, The Lancet.

[52]  M. Thun,et al.  Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. , 2009, The Lancet. Oncology.

[53]  P. Drew,et al.  A Preliminary Study on the Postoperative Survival of Patients Given Aspirin After Resection for Squamous Cell Carcinoma of the Esophagus or Adenocarcinoma of the Cardia , 2009, Annals of Surgical Oncology.

[54]  J. Baron,et al.  Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. , 2009, Journal of the National Cancer Institute.

[55]  Marc Cohen.  Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care. , 2009, Mayo Clinic proceedings.

[56]  D. Bishop,et al.  Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. , 2008, The New England journal of medicine.

[57]  Deepak L. Bhatt,et al.  ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. , 2008, Circulation.

[58]  M. Lai,et al.  Mechanisms underlying aspirin-mediated growth inhibition and apoptosis induction of cyclooxygenase-2 negative colon cancer cell line SW480. , 2008, World journal of gastroenterology.

[59]  R. Gelber,et al.  Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. , 2008, Journal of the National Cancer Institute.

[60]  D. Kerr,et al.  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.

[61]  G. Davı̀,et al.  Platelet activation and atherothrombosis. , 2007, The New England journal of medicine.

[62]  Taghreed Adam,et al.  The burden and costs of chronic diseases in low-income and middle-income countries , 2007, The Lancet.

[63]  Yong J. Lee,et al.  Aspirin Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Hormone-Refractory Prostate Cancer Cells through Survivin Down-Regulation , 2007, Molecular Pharmacology.

[64]  J. Ajani,et al.  Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  M. Parmar,et al.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.

[66]  Sally Hunsberger,et al.  Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  O. Sansom,et al.  Aspirin activates the NF-κB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer , 2006 .

[68]  M. Redlak,et al.  Aspirin-Induced Apoptosis in Human Gastric Cancer Epithelial Cells: Relationship with Protein Kinase C Signaling , 2007, Digestive Diseases and Sciences.

[69]  C. Mathers,et al.  Projections of Global Mortality and Burden of Disease from 2002 to 2030 , 2006, PLoS medicine.

[70]  G. Borthwick,et al.  Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox‐ independent mechanism , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[71]  L. Laine,et al.  Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. , 2006, The American journal of medicine.

[72]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[73]  S. Gutnikov,et al.  Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study) , 2005, The Lancet.

[74]  P. Drew,et al.  Aspirin induces apoptosis in oesophageal cancer cells by inhibiting the pathway of NF‐kappaB downstream regulation of cyclooxygenase‐2 , 2005, ANZ journal of surgery.

[75]  M. Piérart,et al.  Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) , 2005, The Lancet.

[76]  J. Manson,et al.  Low-Dose Aspirin in the Primary Prevention of Cancer: The Women’s Health Study: A Randomized Controlled Trial , 2005, JAMA.

[77]  K. Honn,et al.  Platelets and cancer metastasis: A causal relationship? , 1992, Cancer and Metastasis Reviews.

[78]  J. Massagué,et al.  Platelets and metastasis revisited: a novel fatty link. , 2004, The Journal of clinical investigation.

[79]  M. Anderson,et al.  Review article: management of oesophageal adenocarcinoma — control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus , 2004, Alimentary pharmacology & therapeutics.

[80]  R. Botting,et al.  Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition , 2004, Pharmacological Reviews.

[81]  D. Sliva,et al.  Aspirin inhibits highly invasive prostate cancer cells. , 2003, International journal of oncology.

[82]  D. Alberts,et al.  Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[83]  G. Beck,et al.  A randomized trial of aspirin to prevent colorectal adenomas. , 2003, The New England journal of medicine.

[84]  F. Sinicrope,et al.  Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. , 2002, Cancer research.

[85]  D. Dunson,et al.  Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. , 2002, Cancer research.

[86]  S. Yusuf,et al.  Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events , 2002, Circulation.

[87]  Aller,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2002, The New England journal of medicine.

[88]  P. Shekelle,et al.  The Vulnerable Elders Survey: A Tool for Identifying Vulnerable Older People in the Community , 2001, Journal of the American Geriatrics Society.

[89]  Scott A. Hundahl,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.

[90]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[91]  J. Manson,et al.  Aspirin Use and Colorectal Cancer: Post-Trial Follow-up Data from the Physicians' Health Study , 1998, Annals of Internal Medicine.

[92]  A. D'Amico,et al.  Calculated prostate carcinoma volume , 1998, Cancer.

[93]  J. Morrow,et al.  Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. , 1998, Cancer research.

[94]  D. Alberts,et al.  Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. , 1997, Cancer research.

[95]  S. Ghosh,et al.  Inhibition of NF-kappa B by sodium salicylate and aspirin. , 1994, Science.

[96]  N. Cook,et al.  Estimating the effect of the run-in on the power of the Physicians' Health Study. , 1991, Statistics in medicine.

[97]  J. M. Lang,et al.  The use of a run-in to enhance compliance. , 1990, Statistics in medicine.

[98]  L F Watson,et al.  Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. 1988. , 2007, International journal of epidemiology.

[99]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[100]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[101]  T. Gasic,et al.  Anti-metastatic effect of aspirin. , 1972, Lancet.

[102]  Contemporary Clinical Trials , 2022 .